Oncosec Medical Inc [ONCS]

Source: 

Company Overview

We are a late-stage immuno-oncology company focused on designing, developing and commercializing innovative,proprietary, intra-tumoral DNA-based therapeutics to stimulate and to augment anti-tumor immune responses for the treatment of cancers. Our core technology platform ImmunoPulse is a drug-device therapeutic modality platform comprised of proprietary intratumoral electroporation (EP) delivery devices (the OncoSec Medical System (OMS) Electroporation Device or OMS EP Device) and a proprietary DNA plasmid that triggers transient expression of target protein in cells. The OMS EP Device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer.